Resverlogix Corp. (RVX.TO)

0.0650 +0.0050 (+8.33%) At close: 03:48PM EDT

Resverlogix Corp.

4820 Richard Road SW
Suite 300
Calgary, AB T3E 6L1
Canada
403-254-9252
https://www.resverlogix.com

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 

Key Executives

Name	Title	Pay	Exercised	Year Born
Mr. Aaron Bradley Cann C.A., CPA, CBV	Chief Financial Officer	211.35k	N/A	N/A
Dr. Ewelina Kulikowski Ph.D.	Chief Scientific Officer	250k	N/A	N/A
Dr. Michael Sweeney M.D.	Senior Vice President of Clinical Development	530.68k	N/A	1961
Mr. Donald J. McCaffrey	Co-Founder, Chairman, President, CEO & Secretary	505.2k	N/A	N/A

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in CAD.

Description

Resverlogix Corp., a late-stage clinical biotechnology company, develops therapeutics for patients with chronic illnesses. The company's lead drug is apabetalone (RVX-208), a small molecule selective bromodomain and extra-terminal inhibitor for patients with cardiovascular disease, chronic kidney disease, type 2 diabetes mellitus, low high-density lipoprotein cholesterol, recent acute coronary syndrome, and post COVID-19 conditions. It has a partnership with Eversana Life Science Services, LLC to support the commercialization of apabetalone for COVID-19 in the United States and Canada; and developing cardiovascular and pulmonary arterial hypertension indications. The company is headquartered in Calgary, Canada.

Corporate Governance

Resverlogix Corp.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.